Navidea Biopharmaceuticals Inc.

1.34+0.0400+3.08%Vol 15 4051Y Perf -48.08%
Jan 28th, 2020 16:00
BID1.29 ASK1.35
Open1.31 Previous Close1.30
Pre-Market- After-Market-
 - -%  - -%
Target Price
2.50 
Analyst Rating
Strong Buy 1.00
Potential %
86.57 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
100/100/100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
100/100/100 
Growth Ranking
+ —    -
Insiders Shares Cnt. % 3/6/12 mo.
100/100/100 
Income Ranking
 —    -
Market Cap (M)24 
Earnings Rating
Buy
Price Range Ratio 52W %
22.91 
Earnings Date
5th Mar 2020

Today's Price Range

1.281.36

52W Range

0.49004.20

Summary:

Neutral

Technical Indicators: Sell
Moving Averages: Buy
Performance
1 Week
-7.14%
1 Month
12.07%
3 Months
66.67%
6 Months
120.34%
1 Year
-48.08%
3 Years
-88.39%
5 Years
-95.96%
10 Years
-96.47%

TickerPriceChg.Chg.%
NAVB1.340.04003.08
AAPL317.698.74002.83
GOOG1 452.5618.66001.30
MSFT165.463.18001.96
XOM64.63-0.1100-0.17
WFC47.360.26000.55
JNJ149.500.75000.50
FB217.792.92001.36
GE11.730.29002.53
JPM134.432.40001.82
Earnings HistoryEstimateReportedSurprise %
Q04 2017--0.03-
Q04 2016--0.02-
Q03 2016-0.00-
Q02 2016--0.04-
Q01 2016--0.02-
Q04 2015--0.02-
Q03 2015--0.05-
Q02 2015--0.03-
Earnings Per EndEstimateRevision %Trend
12/2019 QR-0.09--
12/2019 FY-0.49--
12/2020 FY-0.30--
----
Next Report Date5th Mar 2020
Estimated EPS Next Report-0.09
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume15 405
Shares Outstanding (K)18 079
Trades Count290
Dollar Volume123 910
Avg. Volume146 958
Avg. Weekly Volume118 611
Avg. Monthly Volume161 223
Avg. Quarterly Volume633 998
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (100.00 %)
1 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Navidea Biopharmaceuticals Inc.

Navidea Biopharmaceuticals Inc is a biotechnology company specialized in precision medicine. Its products, precision immunodiagnostic agents and immunotherapeutic products, are designed to assist in the identification of undetected diseases and to improve targeted treatment. The company's platform, known as Manocept technology, aims to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases. One of the company's products is Lymphoseek, a radioactive diagnostic agent indicated to locate lymph nodes.

CEO: Jed A. Latkin

Teplephone: +1 614 793-7500

Address: 4995 Bradenton Avenue, Dublin 43017-3552, OH, USA

Number of employees: 19

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

40%60%

Bearish Bullish

54%46%

Bearish Bullish

56%44%

News

Stocktwits